Introduction
Clinically, it is important to predict chemoresponse before initiating chemotherapy. Over the past few decades much research has been directed to the development of chemosensitivity tests [1] [2] [3] , some of which can successfully predict chemoresponse clinically [4] [5] [6] [7] . However, chemosensitivity tests are not used routinely because they are labor-intensive and time-consuming. Moreover, these tests are based on a comparison of the viability of treated and untreated cancer cells, and require a large amount of cancer tissue. It is difficult to obtain large samples of cancer tissue for chemosensitivity tests from patients with unresectable or recurrent cancer who are to undergo chemotherapy. Therefore, it is necessary to develop a chemosensitivity test that can be performed on small biopsy specimens.
Some antineoplastic agents (e.g., topoisomerase inhibitors, DNA reactive drugs, and antimetabolites) have been reported to induce apoptosis [8] [9] [10] [11] [12] [13] . Apoptosis can be detected in small specimens by morphological changes, DNA fragmentation, and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick labeling (the TUNEL assay [14] ). Although apoptosis correlates with chemosensitivity to some antineoplastic agents [15, 16] , a chemosensitivity test based on an examination of apoptosis has not yet been established.
The relationship between apoptosis and chemosensitivity was investigated in order to clarify whether apoptosis can be used as a sensitive assay for chemosensitivity. In this study, apoptosis was detected, using the TUNEL assay, in small specimens of human gastric cancers exposed to antineoplastic agents both in vitro and in animal model.
Methods

Cell culture
The human gastric cancer cell lines, MKN-1 [17] , MKN-45 [17] , and TMK-1 [18] , were cultured in RPMI-1640 medium (Nissui Pharmaceutical, Tokyo, Japan) supplemented with 10% heat-inactivated fetal calf serum (GIBCO BRL, Tokyo, Japan), 4 mM l-glutamine, 10 U/ml penicillin and streptomycin (culture medium) at 37°C in 5% CO2 and 95% air.
Antineoplastic agents
Cisplatin (CDDP) and doxorubicin (DXR) were purchased from Daiichi Pharmaceutical (Tokyo, Japan), and 5-fluorouracil (5-FU) was purchased from Kyowa Hakko Kogyo (Tokyo, Japan). Paclitaxel (Taxol) and SN-38 (active metabolite of irinotecan) were kindly provided by Bristol-Myers Squibb (Tokyo, Japan) and Daiichi Pharmaceutical, respectively. Taxol, CDDP, 5-FU, and SN-38 were stored at 4°C, and DXR dissolved in saline (2 mg/ml) was stored at Ϫ20°C as a stock solution. Each of these agents was diluted with phosphatebuffered saline (PBS) immediately before use.
Chemosensitivity in vitro
The chemosensitivity of the gastric cancer cells in vitro was assessed by the concentration that inhibited cell growth by 50% (IC 50 ). Briefly, MKN-1, MKN-45, and TMK-1 cells were plated in 96-well plates (4 ϫ 10 3 cells/ well), and cultured for 24 h. The antineoplastic agents were then added to triplicate wells (200 µl/well); DXR, CDDP, SN-38, and Taxol were used at concentrations of 0 to 1.0 ϫ 10 1 mg/ml, and 5-FU was used at 0 to 1.0 ϫ 10 1 mg/ml. After 72-h culture, 10 µl of 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) in phosphate-buffered saline (PBS; 0.5 µg/ml) was added to each well (Sigma-Aldrich Japan, Tokyo Japan). (MTT was filtered through a 0.45-µm filter membrane before use.) Four h later, the medium was aspirated carefully and crystals were dissolved by the addition of 200 µl dimethyl sulfoxide to each well. Absorbance was then measured at 540 nm, using an enzyme-linked immunosorbent assay (ELISA) reader. The IC 50 of each antineoplastic agent was calculated for each cancer cell line. 1 µg/ml. After treatment with the individual antineoplastic agent for 24 h, both free and adherent cells were collected, the latter following trypsinization. Cells were collected by centrifuging at 3000 rpm. They were washed three times in PBS and lysed with 0.5 µg/ml proteinase K (Sigma) in lysis buffer (0.5% sodium dodecylsulfate [SDS], 5 mM ethylenediamine tetraacetic acid [EDTA], 10 mM Tris-HCl pH 7.8) at 37°C for 24 h. DNA was extracted with phenol/chloroform, precipitated with ethanol, dissolved in 10 mM Tris-HCl (pH 7.8) and then treated with 0.5 µg/ml RNAse A (Sigma) at 37°C for 1 h.
DNA fragmentation in vitro
DNA was electrophoresed (20 µg/lane, 100 V, 20 min) in 2% agarose gel containing ethidium bromide (0.5 µg/ ml). DNA fragmentation was visualized by UV illumination, and the minimum concentration of each antineoplastic agent required to induce DNA fragmentation (MCIDF) was determined for each cell line.
Drug treatment of small tumor pieces
Cancer cells (1 ϫ 10 7 ) were implanted subcutaneously in 4-week-old female BALB/c nu/nu nude mice (Charles River Japan, Yokohama, Japan). Four weeks later, when the tumors had grown to larger than 1 cm in diameter, the viable part of each tumor was aseptically resected, and then dissected into small pieces of approximately 2-mm diameter. The small tumor pieces were exposed for 24 h to the antineoplastic agents added to culture medium at the following concentrations: DXR, CDDP, SN-38, and Taxol, at 0, 1.0 ϫ 10 Ϫ5 , 1.0 ϫ 10
Ϫ4
, and 1.0 ϫ 10 Ϫ3 µg/ml; and 5-FU, at 0, 1.0 ϫ 10 Ϫ3 , 1 ϫ 10 Ϫ2 , and 1 ϫ 10 Ϫ1 µg/ml.
TUNEL positivity in small tumor pieces
Small tumor pieces, either untreated or treated with antineoplastic agents, were fixed with 10% formalin overnight and embedded in paraffin. Five specimens were aligned in paraffin according to the concentrations of the antineoplastic agent. Four-µm-thick slices were cut from each block, deparaffinized in xylene, and hydrated in graded concentrations of ethanol. After being washed with 100 mM Tris-HCl at pH 7.8, sections were immersed in methanol containing 0.3% H 2 O 2 for 20 min to inhibit endogenous peroxidase activity. The sections were rinsed thrice with distilled water for 2 min each time, and then treated with 10 µg/ml proteinase K in lysis buffer at 37°C for 10 min. The sections were then immersed in terminal deoxynucleotidyl transferase (TdT) (0.3 e.u./ml) (GIBCO, Grand Island, NY, USA) and biotinylated dUTP (0.04 mmol/ml) (GIBCO) in TdT buffer (0.1 M potassium cacodylate, pH 7.2, 2 mM cobalt chloride, 0.2 mM dithiothreitol) (GIBCO) in a humid atmosphere at 37°C for 90 min. The reaction was terminated by transferring the sections to a stopping buffer (300 mM NaCl, 30 mM sodium citrate) for 15 min at room temperature. After being washed thrice with PBS for 2 min each time, sections were incubated in Avidin Biotin Complex (ABC) reagent (Vector Laboratories, Burlingame, CA, USA) for 1 h. The color reaction was developed in 2% 3-3Ј-diaminobenzidine (Sigma) and 0.3% H 2 O 2 in Tris buffer, and the sections were counterstained with methyl green. Cancer cells were distinguished morphologically from stromal cells by microscopic examination (ϫ400) and the percentages of TUNEL-positive cancer cells (TUNEL positivity) were calculated by scoring about 3000 cells in each specimen (five visual fields/ specimen). DNA fragmentation in each small specimen treated with antineoplastic agents was also examined, using methods for examining DNA fragmentation in vitro.
Antitumor effect of Taxol in an animal model
Taxol (9 mg/kg per day) was injected intraperitoneally for 9 consecutive days, beginning 4 weeks after the implantation of MKN-1, MKN-45, and TMK-1 into nude mice (three mice/cell line). The same volume of PBS was injected in a similar manner as a control. The length "a" and width "b" (in mm) of each tumor was measured every 3 days from the first injection to day 12. Tumor weight was calculated as 0.5 ϫ a ϫ b 2 (mg). The relative growth compared with tumor weight on day 0 and relative tumor weight to the control (T/C) were calculated.
Results
IC 50 and minimum concentration inducing DNA fragmentation (MCIDF)
DXR, SN-38, and Taxol induced DNA fragmentation in MKN-45 and in TMK-1 cells, but not in MKN-1. In contrast, 5-FU and CDDP did not induce DNA fragmentation in any of these gastric cancer cell lines. The relationship between in-vitro chemosensitivity (IC 50 ) and MCIDF for DXR, SN-38, and Taxol is shown in Table 1 . The MKN-1 cells did not show DNA fragmentation and had the lowest sensitivity to these three antineoplastic agents. For DXR, the IC 50 s and MCIDFs of MKN-45 and TMK-1 were similar. For SN-38 and Taxol, the IC 50 s and MCIDFs of MKN-45 were lower than those of TMK-1.
DNA fragmentation and TUNEL positivity in small pieces of tumors left untreated
Fewer than 1% of cancer cells in the small tumor pieces fixed immediately after resection showed TUNELpositive cells. TUNEL positivity was detected in fewer than 3% of cancer cells following culture for 24 h in medium containing no antineoplastic agents (Table 2) . However, untreated specimens of all three cancers showed DNA fragmentation after 24-h culture.
TUNEL positivity in small tumor pieces
The percentages of TUNEL-positive cells in all three cancers increased after 24-h treatment with DXR, SN-38, or Taxol. The relationship between TUNEL positivity and IC 50 for each of these three gastric cancers is shown in Fig. 1 .
Although the percentages of TUNEL-positive cells were dose-dependent, in some cases, estimations of the percentages of TUNEL-positive cells at three different concentrations of the antineoplastic agent were consistent with the degree of apoptosis induced in the cancer cell line. TMK-1 had the highest percentage of TUNEL-positive cells after DXR treatment, and MKN-45 had had the highest percentage of TUNEL-positive cells after SN-38 and Taxol treatments. TUNEL positivity correlated with IC 50 s. None of the three 
Chemosensitivity to Taxol in an animal model
Discussion
Chemosensitivity tests in which cancer cells are exposed to antineoplastic agents in suspension are said to fail to mimic in-vivo conditions. Recently, it has been reported that histoculture allows specimens to maintain cell-tocell contact and interaction, and succeeds in mimicking the conditions of drug exposure in vivo [3] . Kubota et al. [5] reported the clinical utility of a histoculture drug response assay in which small tumor pieces were cultured on a sponge gel support for 7 days. In the present study, small tumor tissue specimens preserving cell-tocell contact were cultured for 24 h. TUNEL positivity in untreated specimens was less than 3% (Table 2) . Shortterm culture of untreated tumor specimens may account for the low percentage of TUNEL-positive cells. Shortterm culture of tumor specimens does not appear to induce significance apoptosis.
In this study, MKN-1 did not show DNA fragmentation and was the least sensitive of the cell lines examined in vitro. The MCIDFs of MKN-45 and TMK-1 reflected their IC 50 s for all three antineoplastic agents. MCIDF may be a marker of sensitivity in vitro. However, DNA fragmentation was observed in small pieces of tumors after culturing for 24 h, even without exposure to antineoplastic agents. Some stromal cells surrounding the cancer cells were TUNEL-positive. This may account for DNA fragmentation in untreated small specimens. These results suggest that it is very difficult to assess chemosensitivity by examining MCIDF in small pieces of tumors containing both cancer and stromal cells.
Although TUNEL positivity did not show a clear dose-dependent increase in some cases, it did increase after treatment with DXR, SN-38, and Taxol The expression of markers such as p53 [20, 21] and bcl-2 [22, 23] has been shown to be associated with apoptosis. Because MKN-1 and TMK-1 have point mutations in p53, while MKN-45 has wild-type p53 [24] , it is possible that the status of p53 is related to TUNEL positivity and sensitivity to DXR, SN-38, and Taxol. However, Wahl et al. [25] reported that mutant p53 enhanced sensitivity to Taxol, and the relationship between p53 and chemosensitivity has been reported to depend on the cell type, the antineoplastic agent, the treatment schedule, and the cell cycle. Our methods for assessing chemosensitivity may evaluate antitumor effects more directly than via the status of these genes.
Conclusion
TUNEL positivity in small cancer specimens after exposure to antineoplastic agents reflects chemosensitivity when apoptosis is implicated. Our test for chemosensitivity requires only small specimens that can be obtained by biopsy and may be applicable to chemosensitivity testing clinically. The clinical utility of this method should be investigated in a future prospective study.
